Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, is currently in a Phase 3 study for ...

Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of ...

Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited, who also provides commercial manufacturing for the product. EQ101: a selective tri-specific cytokine ...

Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the ...

Candidate: Itolizumab Category: ANTIBODY Type: First-in-class immune-modulating antibody therapeutic designed to inhibit CD6, in order to reduce the activation and trafficking of pathogenic T ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo ...

Itolizumab could reduce morbidity, mortality in severe cases, says Cuban researchers Beyza Binnur Dönmez | 04.02.2021 - Update : 04.02.2021 File Photo ...

Equillium's strategic partner, Ono Pharmaceutical Co., Ltd., has until late October 2024 to decide on acquiring Equillium's rights to itolizumab for approximately $35 million, with potential ...

Equillium will be responsible for the conduct of all research and development of itolizumab, which will be fully funded by Ono on a quarterly basis commencing July 1, 2022 through the option ...

The study also found that in four out of five patients who received itolizumab, blood levels of proteins that can cause life-threatening inflammation were significantly reduced within 24 to 48 ...

Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells that drive a number of immuno-inflammatory diseases ...